ERBB2 and breast carcinoma: The TAILORx prospective trial examining the use of Oncotype DX scores to stratify treatment in ER+ (and/or progesterone receptor-positive), HER2-, node-negative early advanced breast cancer has reported 5-year results on its low-risk patient cohort assigned to receive endocrine treatment alone [15].